OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy
May 02, 2022 01:30 ET
|
OSE Immunotherapeutics
A new protection covering CLEC-1 antagonists until 2037Patent also granted in Japan and notice of allowance granted in the US NANTES, France, May 02, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics...
OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy
April 04, 2022 12:00 ET
|
OSE Immunotherapeutics
At American Association for Cancer Research Annual (AACR) Meeting 2022New Orleans, April 8 – 13 NANTES, France, April 04, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173;...
OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities
March 30, 2022 12:00 ET
|
OSE Immunotherapeutics
Shared positive final Phase 3 results for Tedopi® in non-small cell lung cancer (NSCLC) patients in secondary resistance after failure with second-line checkpoint inhibitor treatment.Received an €8...
OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer Treatment
March 21, 2022 13:00 ET
|
OSE Immunotherapeutics
Issued by the United States Patent and Trademark Office A New Protection Covering OSE-279 Until 2039 NANTES, France, March 21, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:...
OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine
March 16, 2022 13:00 ET
|
OSE Immunotherapeutics
Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.CoVepiT, based on 13 peptides, elicits durable T-cell immunity...
Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors
March 09, 2022 01:30 ET
|
OSE Immunotherapeutics
At American Association for Cancer Research Annual Meeting 2022New Orleans, April 8 – 13 NANTES, France, March 09, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE),...
OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors
February 18, 2022 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, Feb. 18, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the appointment by cooptation of Alexandre Lebeaut as an independent...
OSE Immunotherapeutics is Pleased to Announce that Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, has Obtained FDA Fast-Track Designation for CD28 Antagonist VEL-101/FR104
February 17, 2022 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, Feb. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, has obtained...
Transfer of OSE Immunotherapeutics’ Shares from Compartment C to Compartment B of Euronext Paris from January 31, 2022
February 01, 2022 01:30 ET
|
OSE Immunotherapeutics
NANTES, France, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that its shares have been transferred from compartment C to compartment B...
OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104
January 31, 2022 12:00 ET
|
OSE Immunotherapeutics
Based on the global license agreement signed in April 2021, this first milestone triggers a €5 million payment from Veloxis Pharmaceuticals, Inc. to OSE Immunotherapeutics. NANTES, France, Jan. ...